Treatment for patients with relapsed or refractory acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and pharmacokinetics of APG-2575, both as a single agent and in combination with HHT or AZA, in patients suffering from relapsed or refractory acute myeloid leukemia (AML) and related myeloid malignancies. It consists of three stages: an initial dose-escalation of APG-2575 alone, followed by a dose-escalation of APG-2575 combined with HHT or AZA, and finally an expansion cohort to determine the maximum tolerated dose and recommended phase 2 dose of the combination regimen. The study is open-label and multi-center, allowing for a diverse patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects who meet each of the following inclusion criteria are eligible to participate in this study:

1. In accordance with the World Health Organization (WHO) 2016 diagnostic criteria for relapsed or refractory acute myeloid leukemia (AML), Mixed phenotype acute leukemia(MPAL), Chronic myelomonocytic leukemia (CMML), Higher-risk myelodysplastic syndrome (HR-MDS) , Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and naïve AML ineligible for treatment with a standard chemotherapy due to age or comorbidities.
2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2 (0 to 3 for participants \>= 60 to 74 years of age who are evaluated as ineligible for treatment with standard chemotherapy).
3. Subjects can accept oral administration of Lisaftoclax (APG-2575).
4. Life expectancy ≥ 3 months.
5. Adequate renal and liver function.
6. Males, female patients of childbearing potential (postmenopausal women who must have been menopausal for at least 12 months to be considered infertile) and their partners voluntarily take contraception which the investigator considers effective during treatment and at least three months after the last dose of study drug.
7. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).
8. Willingness and ability to comply with study procedures and follow-up examination.

Exclusion Criteria:

Patients who meet any of the following exclusion criteria are not to be enrolled in this study:

1. Patients diagnosed with acute promyelocytic leukemia or t(9;22)(q34.1;q11.2); BCR-ABL1 positive AML patients.
2. The persistent toxicities caused by previous chemotherapy or radiotherapy has not been restored to lower than grade 2 by CTCAE 5.0 (except for alopecia).
3. Known leukemia infiltration of the central nervous system.
4. Symptomatic active fungal, bacterial and/or viral infections.
5. Prior history of allogeneic hematopoietic stem cell transplantation or adoptive cell immunotherapy, autologous hematopoietic stem cell transplantation within 12 months.
6. Within 14 days before the first dose of study drug, received chemotherapy (hydroxyurea is permitted more than 24 hours before the first dose of study drug), radiotherapy, surgery, immunotherapy, targeted therapy, biological therapy or any investigational treatment.
7. Within 7 days before the first dose of study drug, received a strong and/or moderate CYP3A inducer and/or Inhibitor.
8. At the discretion of the investigator, gastrointestinal diseases that affect the absorption of Lisaftoclax (APG-2575).
9. Any other condition or circumstance, at the discretion of the investigator, that patients would be unsuitable for participation in the study.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting
• Sun Yat-sen University Cancer Center
  Guangzhou, Guandong, China Recruiting
• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting
• Henan Tumor Hospital
  Zhengzhou, Henan, China Recruiting
• Union Hospital medical college Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting
• Zhongnan Hospital of Hunan university
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Jie Jin, M.D. — the First Affiliated Hospital, College of Medicine
• Study coordinator: Jie Jin, M.D.
• Email: jiej0503@163.com
• Phone: +86 571-87236896

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination treatment for relapsed or refractory acute myeloid leukemia

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory acute myeloid leukemia feel better and improve their treatment results.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06621212

• BG-75202 alone or with other drugs in myeloid malignancies

  This study tests BG-75202, a KAT6A/B inhibitor, alone and with other agents to see if it is safe and potentially helpful for adults with myeloid malignancies.

  Recruiting at 17 sites Phase 1 BeOne Medicines · Concord, New South Wales and 16 other locations · NCT07619287

• RSK1 Inhibitor PMD-026 in myeloid malignancies

  A first-in-human test of PMD-026, an oral drug that blocks RSK1, to see if it is safe and can help reduce spleen size and symptoms in people with myelofibrosis and related myeloid conditions.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07379125

• Considering allogeneic stem cell transplant using digital patient stories and values tools

  This program will test whether digital patient stories plus values-clarification exercises help adults with myeloid cancers who are deciding about allogeneic hematopoietic cell transplantation make choices that fit their goals.

  Recruiting University of Rochester · Rochester, New York · NCT07263074

• Germline testing for inherited risk of myeloid blood cancers

  This research will test whether a germline genetic test (MyeloGen Gene Panel) can find inherited changes linked to myeloid blood cancers in adults who have been diagnosed.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07112287

• Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers

  This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT07044544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.